Bukwang Pharmaceutical its subsidiary Dyna Therapeutics obtained a composition patent for SOL-804, a prostate cancer drug candidate, in Korea and Japan.With the additional two patent registrations, Dyna has completed the patent registration in 32 countries including the U.S., Australia, Mexico, and
Celltrion Healthcare said it has officially begun preparing to directly market its drugs in the U.S. by acquiring Celltrion USA from Celltrion.Celltrion Healthcare and Celltrion believe the acquisition will help maximize profits for both companies by strengthening each company's core competency and
HLB Life Science, which owns rights to market Jiangsu Hengrui Medicine’s anticancer drug pyrotinib in Korea, said it would expand new pipelines on the back of the recent success of a phase 3 pyrotinib trial.Jiangsu Hengrui announced that the phase 3 clinical trial of pyrotinib met the primary endpoi
Kyung Hee University Medical Center (KHMC) said it ranked 10th in the 2021 Inpatient Experience Evaluation conducted by the Health Insurance Review and Assessment Service (HIRA) on 359 general hospitals nationwide.According to the hospital, KHMC received a score of 88.6, ranking tenth among all gene
The Ministry of Health and Welfare recently changed the official English name of “Oriental medical doctor” to “doctor of Korean medicine,” causing a strong backlash from the medical community.Doctors said the new name could be misleading because English-speaking people could confuse Western medical
Professor Virginijus Siksnys of the Institute of Biotechnology at Vilinus University opened the third and final day of Bio-Interplex (BIX) Korea 2022 with the keynote speech on the past, present and future of CRISPR-Cas technology on Friday at COEX, southern Seoul.CRISPR technology gained widespread
SillaJen announced Thursday that it tapped Kim Jae-kyung, a former head of LabGenomics, as the new CEO.With Kim taking the helm, SillaJen said it would be able to normalize stock trading and strengthen corporate transparency.Kim was a founding member and CEO of LabGenomics. He also served as an adju
Ten hypertension generic drugs containing azelnidine in the calcium channel blocker (CCB) class, including Intro Bio Pharma’s Intro Azelnidipine, are eligible for reimbursement, the health insurance review agency said.The Health Insurance Review and Assessment Service (HIRA) released the results of
ATGC said Thursday that it signed a strategic partnership license and supply agreement with RELIFE, an Italian biopharma firm, for its botulinum toxin type A (ATGC-100) as part of its strategic entry into Europe.Under the agreement, ATGC will grant RELIFE exclusive rights to develop, register, promo
The quarantine authorities on Thursday lowered their forecast for the peak of daily Covid-19 cases to 150,000.“According to several mathematical analysis groups, the majority opinion is that the peak will come in August,” said Lee Sang-won, head of the epidemiological investigation and analysis team
On the opening day of Bioplus-Interphex (BIX) Korea 2022 on Wednesday, Korea Biomedical Review (KBR) spoke to a variety of foreign companies to discover their intentions for attending the event this year.At the forefront of discussions was healthcare digitalization.Merck gave an engaging presentatio
Bridge Biotherapeutics announced that it would release non-clinical data of idiopathic pulmonary fibrosis (IPF) treatment candidates BBT-301 and BBT-209 at the IPF summit 2022 to be held at Boston from Aug. 29 to Sept. 1.According to the company, BBT-301 is a novel drug candidate which fights the di
CGBio said it has signed a strategic partnership agreement with Orthofix Medical, a U.S.-based global medical device company, to license out its Novosis Putty, a bone substitute, and supply its finished products to the U.S. and Canada.According to the company, Novosis Putty is a next-generation reco
A joint research team of Korean and U.S. researchers said they found a new cause of senescence in mice.The research team of Professor Jeon Ok-hee at Korea University College of Medicine and Professor Irina Conboy at the University of California, Berkeley, published a paper, titled, “Systemic inducti
Medytox’s plan to enter the Chinese botulinum toxin (BTX) market is suffering a setback as Bloomage Biotechnology, its Chinese partner, announced that it would terminate its deal with Medytox.According to Chinese media outlets, Bloomage has hired a lawyer to issue an official notice to exercise its
Myongji Hospital said it introduced a surgical robot 'CUVIS joint' to increase the precision of joint replacement surgery.Developed by Curexo, a local firm, CUVIS joint automatizes the entire bone cutting process, required before a joint replacement surgery, the hospital said.The surgical robot is e
Biogen’s Alzheimer’s disease treatment Aduhelm (ingredient: aducanumab) may not be able to obtain marketing approval in Korea due to “insufficient data.”According to the minutes of the Central Pharmaceutical Advisory Committee’s meeting disclosed by the Ministry of Food and Drug Safety, the committe
“I was particularly impressed about the company’s mission to save lives. I believe it is more fulfilling to work in the medical field to save other people, like doctors.”So said Joseph Witanto, 27, an assistant manager in Medical IP’s research and development (R&D) division, in a recent interview wi
With the cumulative number of Covid-19 cases surpassing 20 million, the government said that it will promote a “targeted quarantine,” which aims to intensively manage only venues with a high risk of infection.“We have two years and seven months of experience with Covid-19 and a lot of data,” Second
Reyon Pharmaceutical said it would expand business partnerships at the Bioplus-Interphex Korea 2022, Korea’s largest biotech convention held at COEX, Seoul.At the BIX 2022, Reyon Pharmaceutical will seek partners for co-development and CDMO/CMO business by promoting its cGMP biologic drug factory lo